We were fortunate to catch up with European editorial board member Dawn Langdon (Royal Holloway University of London, UK). She talked to us about a clinical tool she developed called BICAMS (Brief international Cognitive Assessment for Multiple Sclerosis), it’s importance and clinical impact so far, as well as next steps.
1. Could you tell us a little about BICAMS (Brief International Cognitive Assessment for Multiple Sclerosis [MS])? (0:04)
2. What impact has BICAMS made on the MS community so far? (0:57)
3. Could you tell us about your latest project – MS Trajectories? (2:11)
Speaker disclosure: Dawn Langdon has nothing to disclose in relation to this video interview.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!